$ Value
—
Shares
3,150
Price
—
Filed
Feb 26
Insider
Name
Hopper Jonathan Mark
Title
Chief Medical Officer
CIK
0001626325
Roles
Transaction Details
Transaction Date
2026-02-24
Code
M
Table
Derivative
Ownership
Direct
Equity Swap
No
Shares After
10,500
Footnotes
The Restricted Stock Units (RSUs) converted to phantom stock units and are deferred under the Vericel Corporation Deferred Compensation Plan. The units will be payable only in shares of Common Stock upon the Reporting Person's elected Benefit Distribution Date. | The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 20, 2025. The remaining RSUs will vest on February 20, 2027, February 20, 2028, and February 20, 2029, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 20, 2025, the Reporting Person deferred the receipt of 350 shares of Common Stock and instead received 350 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan. | These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). | The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 20, 2025. The remaining RSUs will vest on February 20, 2027, February 20, 2028, and February 20, 2029, respectively. | These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs. | The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest on February 22, 2027, and February 22, 2028, respectively. Upon the vesting of RSUs granted to the Reporting Person on February 22, 2024, the Reporting Person deferred the receipt of 1,500 shares of Common Stock and instead received 1,500 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan. | The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 22, 2024. The remaining RSUs will vest on February 22, 2027, and February 22, 2028, respectively. | Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. | No expiration date for this type of award. | The Fair Market Value of the vested derivative securities is $38.09 per share. | The Fair Market Value of the vested derivative securities is $38.25 per share.
Filing Info
Hopper Jonathan Mark's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-04-02 | VCEL | M | $38K |
| 2026-04-02 | VCEL | ▼ | $122K |
| 2026-04-02 | VCEL | M | $0 |
| 2026-02-24 | VCEL | M | — |
| 2026-02-24 | VCEL | M | $0 |
| 2026-02-24 | VCEL | F | $51K |
| 2026-02-24 | VCEL | M | — |
| 2026-02-24 | VCEL | M | $0 |
| 2026-02-24 | VCEL | F | $24K |
| 2026-02-24 | VCEL | M | — |
Other Insiders at VCEL (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
| MCLAUGHLIN KEVIN F | — | $243K | 2026-02-11 |
|
Colangelo Dominick
President and CEO
|
— | — | 2026-02-24 |
| Rubino Alan L | — | — | 2026-03-25 |
| Hagen Heidi | — | $486K | 2026-03-23 |
|
Hopper Jonathan Mark
Chief Medical Officer
|
— | $122K | 2026-04-02 |
|
Halpin Michael
Chief Operating Officer
|
— | $364K | 2026-03-02 |
|
Flynn Sean C.
Chief Legal Officer
|
— | $754K | 2026-03-02 |
|
Mara Joseph Anthony Jr
Chief Financial Officer
|
— | — | 2026-02-24 |
|
SIEGAL JONATHAN
Principal Accounting Officer
|
— | — | 2026-02-24 |